Structure of the molybdenum-cofactor biosynthesis protein MoaB of Escherichia coli.

Acta Crystallogr D Biol Crystallogr

Abteilung Strukturforschung, Max-Planck-Institut für Biochemie, Am Klopferspitz 18a, D-82152 Martinsried, Germany.

Published: June 2004

The moaABC operon of Escherichia coli is involved in early steps of the biosynthesis of the molybdenum-binding cofactor molybdopterin, but the precise functions of the cognate proteins are not known. The crystal structure of the MoaB protein from E. coli was determined by multiple anomalous dispersion at 2.1 angstroms A resolution and refined to an R factor of 20.4% (Rfree = 25.0%). The protein is a 32-symmetric hexamer, with the monomers consisting of a central beta-sheet flanked by helices on both sides. The overall fold of the monomer is similar to those of the MogA protein of E. coli, the G-domains of rat and human gephyrin and the G-domains of Cnx1 protein from A. thaliana, all of which are involved in the insertion of an unknown molybdenum species into molybdopterin to form the molybdenum cofactor. Furthermore, the MoaB protein shows significant sequence similarity to the cinnamon protein from Drosophila melanogaster. In addition to other functions, all these proteins are involved in the biosynthesis of the molybdenum cofactor and have been shown to bind molybdopterin. The close structural homology to MogA and the gephyrin and Cnx1 domains suggests that MoaB may bind a hitherto unidentified pterin compound, possibly an intermediate in molybdopterin biosynthesis.

Download full-text PDF

Source
http://dx.doi.org/10.1107/S0907444904007164DOI Listing

Publication Analysis

Top Keywords

escherichia coli
8
moab protein
8
protein coli
8
molybdenum cofactor
8
protein
7
structure molybdenum-cofactor
4
biosynthesis
4
molybdenum-cofactor biosynthesis
4
biosynthesis protein
4
moab
4

Similar Publications

In Aotearoa New Zealand, urinary tract infections in humans are commonly caused by extended-spectrum beta-lactamase (ESBL)-producing . This group of antimicrobial-resistant bacteria are often multidrug resistant. However, there is limited information on ESBL-producing found in the environment and their link with human clinical isolates.

View Article and Find Full Text PDF

Valorization of mixed blackwater/agricultural wastes for bioelectricity and biohydrogen production: A microbial treatment pathway.

Heliyon

January 2025

African Centre of Excellence in Future Energies and Electrochemical Systems (ACE-FUELS), Federal University of Technology, Owerri, PMB 1526, Imo State, Nigeria.

The management of wastewater and agricultural wastes has been limited by the separate treatment processes, which exacerbate pollution and contribute to climate change through greenhouse gas emissions. Given the energy demands and financial burdens of traditional treatment facilities, there is a pressing need for technologies that can concurrently treat solid waste and generate energy. This study aimed to evaluate the feasibility of producing bioelectricity and biohydrogen through the microbial treatment of blackwater and agricultural waste using a dual-chamber Microbial Fuel Cell (MFC).

View Article and Find Full Text PDF

Lactic acid bacteria (LAB), known for their health benefits, exhibit antimicrobial and antibiofilm properties. This study investigated the cell-free supernatant (CFS) of spp., particularly KR3, against the common foodborne pathogens , and spp.

View Article and Find Full Text PDF

Unlabelled: The persistent challenge posed by antibiotic-resistant bacteria and tuberculosis necessitates innovative approaches to antimicrobial treatment. This study explores the synthesis and characterization of NiZrO₃ nanoparticles integrated with graphene nanoplatelets (GNP) and multi-walled carbon nanotubes (MWCNT), using a microwave-assisted green synthesis route, employing fenugreek () seed extract as a gelling agent. The synthesised nanocomposites were systematically analyzed using XRD, FT-IR, Raman spectroscopy, HR-SEM and HR TEM analysis to assess structural, optical, and morphological properties.

View Article and Find Full Text PDF

Shiga Toxin: Emerging Producer Strains, Prophylactic Approaches, and Application in Cancer Therapy.

J Cancer Prev

December 2024

Infectious Disease Research Center, Avicenna Institute of Clinical Sciences, Hamadan, IranAvicenna Health Research Institute, Hamadan University of Medical Sciences, Hamadan, Iran.

Shiga toxin-producing is the most prevalent bacterial strain responsible for Shiga toxin-related infections. While Shiga toxin is inherently toxic, it has potential therapeutic applications as a component of anticancer drugs. Despite its association with infections and harmful effects on human health, Shiga toxin is being explored as a viable element in drug delivery systems targeting cancer cells.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!